Patients with Colorectal Cancer and BRAF-Mutation in Argentina: A Real-World Study-The EMOGI-CRC01 Study

Area of Science:

• Oncology
• Gastroenterology
• Clinical Research

Background:

• BRAF-mutation is a poor prognostic factor in colorectal cancer (CRC).
• Limited real-world data exists for BRAF-mutated CRC in low-middle-income countries.
• Understanding clinical characteristics and treatment outcomes is crucial.

Purpose of the Study:

• To describe progression-free survival (PFS) in first- and second-line settings for BRAF-mutated advanced CRC.
• To analyze treatment sequences and regimens used in a real-world setting.
• To provide data from Latin America, specifically Argentina.

Main Methods:

• Retrospective analysis of 161 patients with BRAF-mutated advanced CRC.
• Data collected from ten oncology centers in Argentina.
• Patient data spanned from January 2014 to July 2023.

Main Results:

• Median PFS was 9 months in the first-line setting.
• First-line treatment commonly involved doublet chemotherapy plus anti-VEGF (49%).
• BRAF inhibitors were used in 26% of second-line settings, yielding a median PFS of 5.2 months.

Conclusions:

• This is the largest published real-world cohort of BRAF-mutated CRC in Latin America.
• Treatment heterogeneity suggests barriers to accessing high-cost drugs.
• Further cooperative efforts are needed to characterize this patient subgroup.